Projekt SPRINT - Mednarodna mreža za prenos raziskav perinatalnih derivatov v terapevtske pristope

Inštitut za biologijo celice je vključen v evropski projekt z naslovom Mednarodna mreža za prenos raziskav perinatalnih derivatov v terapevtske pristope (The International Network for Translating Research on Perinatal Derivatives into Therapeutic Approaches – SPRINT), ki poteka v okviru programa  COST (Cooperation in Science and Technology). Namen projekta, ki ga je zasnovala prof. dr. Ornella Parolini iz Katoliške univerze Sacro Cuore v Rimu in ki združuje strokovnjake z akademskim, kliničnim in industrijskim znanjem iz 25 držav, je izboljšati bazično razumevanje perinatalnih derivatov in prenesti to znanje v klinično prakso.

V zadnjem desetletju se je pokazalo, da so perinatalni derivati, kot na primer celice placente in bioaktivni faktorji, ki jih te celice izločajo, učinkoviti v terapevtske namene. Raziskovalno področje, ki jih obravnava, hitro raste, pomembnost teh raziskav pa podpira vse več kliničnih študij.

Projekt SPRINT obravnava različna vprašanja, s katerimi se je treba spoprijeti, da bi zagotovili optimalne rezultate raziskav in kar najboljšo interpretacijo podatkov kliničnih testov. To vključuje vzpostavljanje konsenza glede nomenklature perinatalnih derivatov ter glede optimalnih tehnik za njihovo izolacijo, karakterizacijo in krio-konzervacijo. SPRINT obravnava tudi bolj zapletena vprašanja, kot so razumevanje mehanizmov njihovega delovanja in njihovih terapevtskih učinkov ter zbiranje podatkov iz bazičnih raziskav, ki so koristni za oblikovanje kliničnih študij. Poleg tega bo projekt SPRINT pomagal identificirati vrzeli v trenutnem poznavanju perinatalnih derivatov. Tako bodo lahko rezultati projekta pripomogli k smiselnemu usmerjanju prihodnjih raziskav in k poenostavitvi prenosa raziskovalnih ugotovitev v klinično prakso.

Projekt razvija platformo za izmenjavo idej in metod ter skrbi za usposabljanje mladih raziskovalcev. Rezultati, dobljeni s to akcijo COST, bodo povečali vpliv znanstvenih raziskav na javne in zasebne organe odločanja, na združenja bolnikov in tudi na lokalne skupnosti.

Več o projektu si lahko preberete na naslednjih povezavah: www.sprint-cost.org in www.cost.eu/COST_Actions/ca/CA17116 ali kontaktirate prof. dr. Matejo Erdani Kreft (mateja.erdani(at)mf.uni-lj.si).

 

 

English: 

International Network for Translating Research on Perinatal Derivatives into Therapeutic Approaches (SPRINT) 

The International Network for Translating Research on Perinatal Derivatives into Therapeutic Approaches  - SPRINT is a COST (Cooperation in Science and Technology) project that allows excellent researchers and clinicians in the field of innovation to cooperate and jointly develop their ideas in scientific and technology sectors.  The SPRINT project, proposed and coordinated by Professor Ornella Parolini (Università Cattolica del Sacro Cuore, Rome, Italy), brings together experts in terms of academic, clinical, and industrial knowledge from over 25 international countries, in order to improve the basic understanding and the clinical translation of perinatal derivatives.  In the last decade different perinatal derivatives (such as placenta-derived cells and the bioactive factors secreted by these cells), have proven to be therapeutically effective. This research field is growing rapidly and its importance is supported by recent clinical studies carried out in Europe and worldwide.  SPRINT deals with different issues that need to be faced in order to ensure optimal research results and interpretation of clinical trial data. These include obtaining consensus for the nomenclature and for the optimal techniques for the isolation, characterization, cryopreservation, and expansion of perinatal derivatives. SPRINT also addresses more complex issues, such as the understanding of mechanisms and therapeutic actions of perinatal derivatives and the collection of basic research data useful for designing clinical trials. Furthermore, SPRINT helps to identify research gaps so as to guide future research on perinatal derivatives and streamline translation to the clinic.  This project develops a platform for the exchange of ideas and methods and for the training of young researchers. The results obtained from this COST Action will increment the impact of the research on public and private decision-making bodies, on Patient Associations, and also on local communities.   
 
For more information on the SPRINT COST Action and/or to join our Action visit the Action website  www.sprint-cost.org and www.cost.eu/COST_Actions/ca/CA17116 or contact prof. dr Mateja Erdani Kreft (mateja.erdani(at)mf.uni-lj.si).